Walgreens Expands Specialty Pharmacy Business To Include Gene and Cell Services: Details
Walgreens Expands Specialty Pharmacy Business To Include Gene and Cell Services: Details
Retail pharmacy giant Walgreens Boots Alliance Inc (NASDAQ:WBA) is bolstering its specialty pharmacy services, aiming to enhance patient outcomes and value for stakeholders.
零售藥房巨頭Walgreens Boots Alliance Inc（納斯達克股票代碼：WBA）正在加強其專業藥房服務，旨在提高患者療效和利益相關者的價值。
The company unveiled Walgreens Specialty Pharmacy, an encompassing initiative to cater to patients with complex, chronic conditions while fostering profitable partnerships.
該公司推出了Walgreens Specialty Pharmacy，這是一項全面的計劃，旨在滿足複雜慢性病患者的需求，同時促進盈利的合作伙伴關係。
Read Next: Walgreens Challenges Nearly $1B Arbitration Award Over Alleged Breach of COVID-19 Test Business Contract
閱讀下一頁：沃爾格林因涉嫌違反 COVID-19 測試商業合同對近 10 億美元的仲裁裁決提出質疑
Walgreens Specialty Pharmacy introduces a comprehensive suite of services, including gene and cell therapy solutions, marking a significant advancement in the company's healthcare offerings.
Walgreens Specialty Pharmacy推出了一整套服務，包括基因和細胞療法解決方案，這標誌着該公司醫療保健產品的重大進步。
Anchored by an 18,000-square-foot Innovation Center in Pittsburgh, Pennsylvania, the initiative focuses on managing therapy complexities and ensuring patient success.
該計劃由賓夕法尼亞州匹茲堡佔地18,000平方英尺的創新中心主持，側重於管理治療的複雜性並確保患者成功。
Under the expanded business, Walgreens will operate four central specialty pharmacies, each with national accreditations and expertise in dispensing intricate medications.
在擴大的業務下，沃爾格林將經營四家中央專業藥房，每家藥房均獲得國家認證和配發複雜藥物方面的專業知識。
Additionally, the company's expansive network comprises nearly 300 community-based specialty pharmacies, strategically positioned for swift medication access and tailored patient services.
此外，該公司龐大的網絡包括近300家以社區爲基礎的專業藥房，這些藥房處於戰略地位，可快速獲得藥物和提供量身定製的患者服務。
Also Read: Walgreens Boots Alliance Cuts Higher End Of 2024 Profit Outlook, Takes $5.8B Impairment Charge Related To VillageMD Business
另請閱讀: Walgreens Boots Alliance下調了2024年底的利潤展望，收取了與VillageMD業務相關的58億美元減值費用
With over 1,500 specialty-trained pharmacists and 5,000 patient advocacy support members, Walgreens Specialty Pharmacy is primed to address the burgeoning demand for specialized care.
沃爾格林專業藥房擁有1,500多名受過專業培訓的藥劑師和5,000名患者權益支持成員，已準備好滿足對專業護理不斷增長的需求。
Specialty medications constitute a significant portion of the U.S. prescription drug market, driving the need for tailored solutions.
特種藥物佔美國處方藥市場的很大一部分，推動了對量身定製解決方案的需求。
Walgreens Specialty Pharmacy aims to meet this demand by streamlining care coordination across stakeholders, thereby enhancing patient access and driving cost efficiencies.
Walgreens Specialty Pharmacy旨在通過簡化利益相關者之間的護理協調來滿足這一需求，從而增加患者就診機會並提高成本效率。
Effective August 1, 2024, AllianceRx Walgreens Pharmacy will transition to Walgreens Specialty Pharmacy, offering enhanced resources and clinical support to patients.
自2024年8月1日起，AlliancerX Walgreens Pharmacy將過渡到沃爾格林專業藥房，爲患者提供更多的資源和臨床支持。
Walgreens stock lost over 48% in the last 12 months. Investors can gain exposure to the stock via Invesco High Yield Equity Dividend Achievers ETF (NASDAQ:PEY) and Invesco Dow Jones Industrial Average Dividend ETF (NYSE:DJD).
在過去的12個月中，沃爾格林的股票下跌了48％以上。投資者可以通過景順高收益股票分紅ETF（納斯達克股票代碼：PEY）和景順道瓊斯工業平均股息ETF（紐約證券交易所代碼：DJD）獲得股票敞口。
Price Action: WBA shares are trading higher by 0.79% at $17.94 in premarket at last check Thursday.
價格走勢：在週四的最後一次盤前檢查中，WBA股價上漲0.79％，至17.94美元。
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
免責聲明: 該內容部分是在 AI 工具的幫助下製作的，由 Benzinga 編輯審閱和發佈。
Photo via Wikimedia Commons
照片來自維基共享資源
譯文內容由第三人軟體翻譯。